Literature DB >> 25497264

Long-term clinical and angiographic outcomes in patients with diabetes undergoing coronary artery bypass graft surgery: results from the Project of Ex-vivo Vein Graft Engineering via Transfection IV trial.

Masaya Koshizaka1, Renato D Lopes1, Eric M Reyes2, C Michael Gibson3, Phillip J Schulte1, Gail E Hafley1, Adrian F Hernandez1, Jennifer B Green1, Nicholas T Kouchoukos4, Robert M Califf5, T Bruce Ferguson6, Eric D Peterson1, John H Alexander7.   

Abstract

BACKGROUND: There is limited information about the association between diabetes, its treatment, and long-term angiographic and clinical outcomes in patients undergoing coronary artery bypass graft surgery (CABG). We evaluated the association of diabetes and its treatment with 1-year angiographic graft failure and 5-year clinical outcomes in patients undergoing CABG.
METHODS: Using data from 3,014 patients in PREVENT IV, we analyzed angiographic and clinical outcomes in patients with and without diabetes and among those who did and did not receive insulin before CABG. Logistic regression and Cox proportional hazards models were used to adjust for differences in baseline variables.
RESULTS: Overall, 1,139 (37.8%) patients had diabetes. Of these, 305 (26.8%) received insulin. One-year rates of vein graft failure were similar in patients with and without diabetes but, among diabetics, tended to be higher in patients who received insulin compared with those who did not. At 5 years, rates of death, myocardial infarction, or revascularization were higher among patients with compared with those without diabetes (adjusted hazard ratio 1.57; 95% CI 1.26-1.96; P < .001) and, among diabetics, higher among those who received insulin (adjusted hazard ratio 1.15; 95% CI 1.02-1.30; P = .02).
CONCLUSIONS: Patients with diabetes had similar rates of vein graft failure but worse clinical outcomes than patients without diabetes. Patients who received insulin had significantly worse clinical outcomes than patients who did not receive insulin. Further studies to better understand the mechanism behind these findings and to improve the outcomes of patients with insulin-requiring diabetes undergoing CABG surgery are warranted.
Copyright © 2014 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Year:  2014        PMID: 25497264     DOI: 10.1016/j.ahj.2014.10.013

Source DB:  PubMed          Journal:  Am Heart J        ISSN: 0002-8703            Impact factor:   4.749


  10 in total

Review 1.  Comparing the Clinical Outcomes Between Insulin-treated and Non-insulin-treated Patients With Type 2 Diabetes Mellitus After Coronary Artery Bypass Surgery: A Systematic Review and Meta-analysis.

Authors:  Krishna Munnee; Pravesh K Bundhun; Hongzhi Quan; Zhangui Tang
Journal:  Medicine (Baltimore)       Date:  2016-03       Impact factor: 1.889

2.  Which factor is the most effective one in metabolic Sydrome on the outcomes after coronary artery bypass graft surgery? A cohort study of 5 Years.

Authors:  Lijuan Wang; Xiangyang Qian; Mingya Wang; Xinran Tang; Hushan Ao
Journal:  J Cardiothorac Surg       Date:  2018-01-04       Impact factor: 1.637

3.  Impact of type 2 diabetes mellitus on short- and long-term mortality after coronary artery bypass surgery.

Authors:  Alexander Kogan; Eilon Ram; Shany Levin; Enrique Z Fisman; Alexander Tenenbaum; Ehud Raanani; Leonid Sternik
Journal:  Cardiovasc Diabetol       Date:  2018-11-29       Impact factor: 9.951

Review 4.  Review of risk factors, treatment, and prevention of saphenous vein graft disease after coronary artery bypass grafting.

Authors:  Jing Gao; Yin Liu; Yu-Ming Li
Journal:  J Int Med Res       Date:  2018-09-04       Impact factor: 1.671

5.  Advanced glycation end products impair the functions of saphenous vein but not thoracic artery smooth muscle cells through RAGE/MAPK signalling pathway in diabetes.

Authors:  Yongxin Sun; Le Kang; Jun Li; Huan Liu; Yulin Wang; Chunsheng Wang; Yunzeng Zou
Journal:  J Cell Mol Med       Date:  2016-06-14       Impact factor: 5.310

6.  Haptoglobin 2-2 Phenotype Is Associated With Increased Acute Kidney Injury After Elective Cardiac Surgery in Patients With Diabetes Mellitus.

Authors:  Chenzhuo Feng; Bhiken I Naik; Wenjun Xin; Jennie Z Ma; David C Scalzo; Swapna Thammishetti; Robert H Thiele; Zhiyi Zuo; Jacob Raphael
Journal:  J Am Heart Assoc       Date:  2017-10-05       Impact factor: 5.501

Review 7.  Impact of type 2 diabetes mellitus on the long-term mortality in patients who were treated by coronary artery bypass surgery: A systematic review and meta-analysis.

Authors:  Pravesh K Bundhun; Akash Bhurtu; Jun Yuan
Journal:  Medicine (Baltimore)       Date:  2017-06       Impact factor: 1.889

8.  Type 2 diabetes mellitus increases the mortality risk after acute coronary syndrome treated with coronary artery bypass surgery.

Authors:  Eilon Ram; Leonid Sternik; Robert Klempfner; Zaza Iakobishvili; Enrique Z Fisman; Alexander Tenenbaum; Elchanan Zuroff; Yael Peled; Ehud Raanani
Journal:  Cardiovasc Diabetol       Date:  2020-06-13       Impact factor: 9.951

9.  Left ventricular function outcome after coronary artery bypass grafting, King Abdullah Medical City (KAMC)- single-center experience.

Authors:  Sheeren Khaled; Ehab Kasem; Ahmed Fadel; Yusuf Alzahrani; Khadijah Banjar; Wafa'a Al-Zahrani; Hajar Alsulami; Mazad Ali Allhyani
Journal:  Egypt Heart J       Date:  2019-08-05

10.  Impact of Atherogenic Indexes in Saphenous Vein Graft Stenosis.

Authors:  Fethi Yavuz; Salih Kilic; Mehmet Kaplan; Arafat Yıldırım; Mehmet Kucukosmanoglu; Mustafa Dogdus
Journal:  Arq Bras Cardiol       Date:  2020-09       Impact factor: 2.667

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.